[Antinucleolar antibodies in diagnostics of antiphospholipid syndrome].

Pol Arch Med Wewn

Department of Microbiology and Serology, Eleonora Reicher Rheumatology Institute, Warszawa, Poland.

Published: September 2009

Introduction: Anti "nucleolar" antibodies are estimated to be present in about 5-10% of anti-nuclear antibodies-positive (ANA), but only in about 15% of cases (sometimes in lower percentages) it is possible to assess precisely the specificity of antibodies responsible for this pattern of ANA. Nucleoli are composed of many proteins, e.g., nucleolin, fibrillarin, Pm-Scl (spliceosome component), RNA-polymerases and different sizes rRNA transcripts. Nucleoli also contain annexins (ANX) II and V. Many of these proteins are target molecules for autoantibodies generated in connective tissue diseases (CTD)--especially in scleroderma and overlap syndromes.

Objectives: The aim of this study was to work out methods for differentiation of antibody specificities in the case of sera ANA-positive with the nucleolar pattern in indirect immunofluorescence (IIF), with a particular concern directed to anti-Annexin V antibodies (belonging to anticofactor antibody system--characteristic of antiphospholipid syndrome [APS]).

Patients And Methods: In the sera of the tested group of 12 (selected from 150 subjects suffering from different kinds of CTD) ANA-positive (Western-blott negative) and showing the nucleolar type of ANA pattern patients, the following autoantibodies were assessed: ANA-IIF, anti-Pm-Scl (overlap syndrome marker), anticardiolipin, antiannexin V, anti-RNA-ase--all using the ELISA method. With the use of the Western-blott method a basic set "marker" autoantibody in CTD was estimated, and the RNA-ase was used for elimination (by enzymatic digestion) of RNA-s and RNA-protein complexes--a possible target for autoantibodies giving the nucleolar pattern.

Results: In 5 out of 12 sera (41.7%) of ANA-positive/Western-blott-negative CTD patients antibodies against Annexin V, cardiolipin, Pm-Scl were detected. In 2 out of 12 patient sera antibodies to the RNA-ase were found. None of the tested sera showed the presence of autoantibodies against antigen Scl-70 (scleroderma marker), and SS-A (Sjögren syndrome marker), which can also give the atypical nucleolar ANA-pattern. Only in few sera "my ositis"--blotts showed antibodies to antigen Ku (nuclear protein), Jo-1 and PI-7 (anti-tRNA synthetases--polymyositis markers)--myositis and overlap syndrome markers. In 80% of tested sera the co-appearance of anti-ANX-V and anticardiolipin antibodies was observed. The presence of antibodies against ANX-V together with Pm-Scl was confirmed in 60% of sera The RNA-ase, used as a specific rRNA and RNP-protein blocker, resulted in a partial or total disappearance of the "nucleolar" pattern, but independently of the tested serum specificity (anti-ANX-V, anti-Pm-Scl or both together). The observed RNA-ase treatment of the Hep-2 cells effects are equivocal and they may result from either binding or digestion the antigen by the RNA-ase, but also from forming a sterical hindrance for the autoantigen binding to another "nucleolar" antigens.

Conclusions: These preliminary results are interesting, especially as concerns anti-ANX-V autoantigens (associated with APS), but they require further research including bigger groups of CTD patients.

Download full-text PDF

Source

Publication Analysis

Top Keywords

antibodies
8
sera
8
overlap syndrome
8
syndrome marker
8
ctd patients
8
tested sera
8
rna-ase
5
[antinucleolar antibodies
4
antibodies diagnostics
4
diagnostics antiphospholipid
4

Similar Publications

Antigen-presenting cells (APCs) process tumor vaccines and present tumor antigens as the first signals to T cells to activate anti-tumor immunity, which process requires the assistance of co-stimulatory second signals on APCs. The immune checkpoint programmed death ligand 1 (PD-L1) not only mediates the immune escape of tumor cells but also acts as a co-inhibitory second signal on APCs. The serious dysfunction of second signals due to the high expression of PD-L1 on APCs in the tumor body results in the inefficiency of tumor vaccines.

View Article and Find Full Text PDF

Tungsten disulphide nanosheet modulated fluorescent gold nanocluster immunoprobe for the detection of tau peptide: Alzheimer's disease biomarker.

Anal Methods

January 2025

Department of Chemistry, School of Physical and Mathematical Science, Research Centre, University of Kerala, Kariavattom Campus, Thiruvananthapuram, Kerala, 695581, India.

The neuronal tau peptide serves as a key biomarker for neurodegenerative diseases, specifically, Alzheimer's disease, a condition that currently has no cure or definitive diagnosis. The methodology to noninvasively detect tau levels from body fluids remains a major hurdle for a rapid and simple diagnostic approach. Thus, developing new detection methods for sensing tau protein levels is crucial.

View Article and Find Full Text PDF

Case report of the successful treatment of pemphigus vulgaris using ovine forestomach matrix graft.

J Surg Case Rep

January 2025

Department of Medical Affairs, Aroa Biosurgery Limited, 64 Richard Pearse Drive, Auckland 2022, New Zealand.

Pemphigus vulgaris (PV) is a subtype of pemphigus and life-altering disorder that results in the formation of intraepithelial blisters in mucosa and skin. Though the etiology is not well understood, it is an autoimmune disorder resulting in acantholytic blisters due to auto-antibodies targeting proteins of keratinocyte adhesion. Rapid diagnosis and restoration of the epidermal layer is imperative for patients with PV as widespread epidermal damage can lead to high morbidity and mortality rates.

View Article and Find Full Text PDF

Background: The proportion of people living with HIV (PLWHIV) co-infected with HCV in Mexico was unknown. Our aim was to estimate the seroprevalence of HCV among adults with HIV in Mexico.

Methods: Using a complex-survey design, we collected blood samples and applied structured questionnaires between May 2nd, 2019 and February 17th, 2020 in a nationally, representative sample of adults receiving care for HIV-infection in 24 randomly selected HIV-care centres in 8 socio-demographically regions in Mexico.

View Article and Find Full Text PDF

Enhancing NK cell-mediated tumor killing of B7-H6 cells with bispecific antibodies targeting allosteric sites of NKp30.

Mol Ther Oncol

March 2025

Early Protein Supply and Characterization, Merck Healthcare KGaA, 64293 Darmstadt, Germany.

In this work, we report the discovery and engineering of allosteric variable domains of the heavy chain (VHHs) derived from camelid immunization targeting NKp30, an activating receptor on natural killer (NK) cells. The aim was to enhance NK cell-mediated killing capacities by identifying VHHs that do not compete with the natural ligand of NKp30:B7-H6, thereby maximizing the recognition of B7-H6 tumor cells. By relying on the DuoBody technology, bispecific therapeutic antibodies were engineered, creating a panel of bispecific antibodies against NKp30xEGFR (cetuximab moiety) or NKp30xHER2 (trastuzumab moiety), called natural killer cell engagers (NKCEs).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!